Mo1388 INCLUSION AND EXCLUSION CRITERIA OF CLINICAL TRIALS AFFECT RESULT APPLICABILITY TO A CLINICAL BARIATRIC PATIENT POPULATION
(Source: Gastroenterology)
Source: Gastroenterology - May 6, 2024 Category: Gastroenterology Authors: Prakash Vasanthakumar, Vic Velanovich Tags: SSAT Abstracts Source Type: research
Advancing cell-based therapy in sepsis: An anesthesia outlook
Chin Med J (Engl). 2024 May 6. doi: 10.1097/CM9.0000000000003097. Online ahead of print.ABSTRACTSepsis poses a health challenge globally owing to markedly high rates of morbidity and mortality. Despite employing bundle therapy over two decades, approaches including transient organ supportive therapy and clinical trials focusing on signaling pathways have failed in effectively reversing multiple organ failure in patients with sepsis. Prompt and appropriate perioperative management for surgical patients with concurrent sepsis is urgent. Consequently, innovative therapies focused on remedying organ injuries are necessitated. ...
Source: Chinese Medical Journal - May 6, 2024 Category: General Medicine Authors: Hui Ye Xiaoyu Zou Xiangming Fang Source Type: research
Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
Clin Pharmacol Ther. 2024 May 6. doi: 10.1002/cpt.3273. Online ahead of print.ABSTRACTTargeted protein degraders (TPDs), an emerging therapeutic modality, are attracting considerable interest with the promise to address disease-related proteins that are not druggable with conventional small molecule inhibitors. Despite their novel mechanism of action, the PK/PD relationship of degraders is still approached with a mindset deeply rooted in inhibitor drugs. Here, we establish how predictive mechanistic modeling specifically tailored to TPDs can significantly enhance the value of the available information during lead generatio...
Source: Clinical Pharmacology and Therapeutics - May 6, 2024 Category: Drugs & Pharmacology Authors: Robin Thomas Ulrich Haid Andreas Reichel Source Type: research
Combination immunotherapy with vaccine and oncolytic HSV virotherapy is time dependent
CONCLUSIONS: These findings substantiate the criticality of combination immunotherapy timing and provide preclinical support for combining SNAPvax with oHSV as a promising treatment approach for both pediatric and adult tumors.PMID:38710101 | DOI:10.1158/1535-7163.MCT-23-0873 (Source: Herpes)
Source: Herpes - May 6, 2024 Category: Infectious Diseases Authors: Stacie K Totsch Andrew S Ishizuka Kyung-Don Kang Sam E Gary Abbey Rocco Aaron E Fan Li Zhou Pablo A Valdes SeungHo Lee Jason Li Luca Peruzzotti-Jametti Sarah Blitz Christopher M Garliss James M Johnston James M Markert Geoffrey M Lynn Joshua D Bernstock G Source Type: research
Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
Rev Endocr Metab Disord. 2024 May 6. doi: 10.1007/s11154-024-09884-y. Online ahead of print.ABSTRACTChildhood obesity is a chronic inflammatory epidemic that affects children worldwide. Obesity affects approximately 1 in 5 children worldwide. Obesity in children can worsen weight gain and raise the risk of obesity-related comorbidities like diabetes and non-alcoholic fatty liver disease (NAFLD). It can also negatively impact the quality of life for these children. Obesity disrupts immune system function, influencing cytokine (interleukins) balance and expression levels, adipokines, and innate and adaptive immune cells. The...
Source: ENDOCR REV - May 6, 2024 Category: Endocrinology Authors: Amin Ullah Rajeev K Singla Zahra Batool Dan Cao Bairong Shen Source Type: research
A Systematic Review of Herbal Interventions for the Management of Cardiovascular Diseases
CONCLUSION: This comprehensive review highlights the potential of herbal interventions as valuable adjuncts or alternatives for managing cardiovascular diseases. Herbal remedies offer diverse mechanisms of action, targeting key CVD risk factors and pathways. While promising, their clinical utility warrants further investigation through well-designed trials to establish their safety and efficacy, paving the way for integrated approaches to cardiovascular disease management. Healthcare providers and patients should engage in informed discussions about the use of herbal interventions alongside conventional therapies in the co...
Source: Current Cardiology Reviews - May 6, 2024 Category: Cardiology Authors: Ankita Wal Neha Verma Senthil Kumar Balakrishnan Vinod Gahlot Sumeet Dwivedi Pankaj Kumar Sahu Mohammad Tabish Pranay Wal Source Type: research
Three-dimensional imaging analysis of CAD/CAM custom-milled versus prefabricated allogeneic block remodelling at 6 months and long-term follow-up of dental implants: A retrospective cohort study
CONCLUSION: The clinical performance of both allograft block designs was equally satisfactory for vertical and horizontal bone grafting prior to implant placement.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT06027710.PMID:38710641 | DOI:10.1111/jcpe.13995 (Source: Journal of Clinical Periodontology)
Source: Journal of Clinical Periodontology - May 6, 2024 Category: Dentistry Authors: Anna Seidel Yago Leira Pilar Batalla Leticia Caneiro Manfred Wichmann Juan Blanco Source Type: research
Minimally invasive non-surgical periodontal therapy of intrabony defects: A prospective multi-centre cohort study
CONCLUSIONS: Improvements in clinical and radiographic outcomes were seen after MINST. This study highlights the generalizability and wide applicability of this approach, further supporting its effectiveness in the treatment of intrabony defects.CLINICAL TRIAL REGISTRATION: NCT03741374. https://clinicaltrials.gov/study/NCT03741374?cond=minimally%20invasive%20non%20surgical%20therapy&locStr=UK&country=United%20Kingdom&distance=50&rank=2.PMID:38710583 | DOI:10.1111/jcpe.13984 (Source: Journal of Clinical Periodontology)
Source: Journal of Clinical Periodontology - May 6, 2024 Category: Dentistry Authors: Jaimini Mehta Marco Montevecchi Ruben Garcia-Sanchez Olanrewaju Onabolu Antonio Li ñares Fernando Eriksson Carlo Ghezzi Camilla Donghi Emily Ming-Chieh Lu Luigi Nibali Source Type: research
Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)
CONCLUSION: BCS 1-5 years after completing chemotherapy with documented memory problems, randomly assigned to 24 weeks of 5-10 mg of donepezil once daily, did not perform differently at the end of treatment on tests of memory, other cognitive functions, or subjective functioning than those randomly assigned to placebo.PMID:38709986 | DOI:10.1200/JCO.23.01100 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Stephen R Rapp Emily V Dressler W Mark Brown James L Wade Nguyet Le-Lindqwister David King Kendrith M Rowland Kathryn E Weaver Heidi D Klepin Edward G Shaw Glenn J Lesser Source Type: research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research
Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)
CONCLUSION: BCS 1-5 years after completing chemotherapy with documented memory problems, randomly assigned to 24 weeks of 5-10 mg of donepezil once daily, did not perform differently at the end of treatment on tests of memory, other cognitive functions, or subjective functioning than those randomly assigned to placebo.PMID:38709986 | DOI:10.1200/JCO.23.01100 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Stephen R Rapp Emily V Dressler W Mark Brown James L Wade Nguyet Le-Lindqwister David King Kendrith M Rowland Kathryn E Weaver Heidi D Klepin Edward G Shaw Glenn J Lesser Source Type: research
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241249690. doi: 10.1177/15330338241249690.ABSTRACTBACKGROUND: Cadonilimab (AK104) is a bispecific IgG-single-chain Fv fragment (ScFv) antibody that binds to PD-1 and CTLA-4. Cadonilimab has shown encouraging anti-tumour activity and a favourable safety profile in several tumour types. In second-line treatment, there is no defined standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC). Cadonilimab is expected to show substantial clinical efficacy.OBJECTIVE: To assess the antitumor activity and safety of cadonilimab monotherapy or combination with...
Source: Technology in Cancer Research and Treatment - May 6, 2024 Category: Cancer & Oncology Authors: Can Chen Minjun Chen Yuju Bai Yajun Li Jie Peng Biao Yao Jiangping Feng Jian-Guo Zhou Hu Ma Source Type: research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research
Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration
Endocr J. 2024 May 3. doi: 10.1507/endocrj.EJ23-0680. Online ahead of print.ABSTRACTShort stature with IGF-1 receptor (IGF1R) gene alteration is known as small-for-gestational-age (SGA) short stature with elevated serum IGF1 levels. Its prevalence and clinical characteristics remain unclear. No adapted treatment is available for short stature related to IGF1R gene alteration in Japan, and genetic testing is not yet widely accessible. We investigated short stature with IGF1R gene alterations and analyzed the clinical data of 13 patients using the results of questionnaires issued to the Japanese Society for Pediatric Endocri...
Source: Endocrine Journal - May 6, 2024 Category: Endocrinology Authors: Yuki Kawashima-Sonoyama Keisuke Wada Kei Yamamoto Masanobu Fujimoto Noriyuki Namba Takeshi Taketani Source Type: research
